Aurealis Pharma, Kuopio (FI)

https://www.aurealispharma.com

Aurealis Pharma is a Basel, Switzerland and Kuopio, Finland based privately-held biopharmaceutical company focusing on developing broadly applicable proprietary technology to re-educate the distorted host immune microenvironment in chronic inflammation and cancer to its proper state. Company’s technology is based on safe food-grade lactic acid bacteria delivering multiple human therapeutic proteins in target tissue effectively, safely and economically to address the unmet medical need in chronic wounds and cancer. *

	Start	2017-08-25 existent
	Group	Aurealis Pharma AG
	Industry	biopharmaceutical
	Industry 2	recombinant protein production in bacterial cells
	Person	Yrjänheikki, Juha (Aurealis Pharma 201708 CEO)

	Region	Kuopio
	Country	Finland
	Street	1 Microkatu
	City	70210 Kuopio
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Aurealis Pharma. (8/25/17). "Press Release: Aurealis Pharma Announces 5.6MCHF Series A Financing to Advance Chronic Wound and Oncology Lead Products". Basel & Kuopio.

		Record changed: 2024-02-12

Picture EBD Group World of Partnering Opportunities 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)